• Profile
Close

A systematic literature review and network meta-analysis comparing once-weekly semaglutide with other GLP-1 receptor agonists in patients with type 2 diabetes previously receiving basal insulin

Diabetes Therapy May 04, 2018

Witkowski M, et al. - Authors probed the efficacy and safety of once-weekly semaglutide vs other glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) in patients with type 2 diabetes (T2D) inadequately controlled on basal insulin. Yielded results demonstrated that once-weekly semaglutide 1.0 mg as an add-on to basal insulin was possibly the most efficacious GLP-1 RA for reducing HbA1c and weight from baseline after 6 months of treatment. The efficacy of once-weekly semaglutide did not appear to be related to a marked increase in the incidence of gastrointestinal side-effects vs other GLP-1 RAs.
Full text available Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay